| Literature DB >> 35531185 |
Mohamed A Hassan1, Sarah Abd El-Aziz2,3, Horeya M Elbadry3, Samy A El-Aassar3, Tamer M Tamer2.
Abstract
Multi-drug resistant (MDR) bacteria associated with wounds are extremely escalating. This study aims to survey different wounds in Alexandria hospitals, North Egypt, to explore the prevalence and characteristics of MDR bacteria for future utilization in antibacterial wound dressing designs. Among various bacterial isolates, we determined 22 MDR bacteria could resist different classes of antibiotics. The collected samples exhibited the prevalence of mono-bacterial infections (60%), while 40% included poly-bacterial species due to previous antibiotic administration. Moreover, Gram-negative bacteria showed dominance with a ratio of 63.6%, while Gram-positive bacteria reported 36.4%. Subsequently, the five most virulent bacteria were identified following the molecular approach by 16S rRNA and physiological properties using the VITEK 2 automated system. They were deposited in GenBank as Staphylococcus haemolyticus MST1 (KY550377), Pseudomonas aeruginosa MST2 (KY550378), Klebsiella pneumoniae MST3 (KY550379), Escherichia coli MST4 (KY550380), and Escherichia coli MST5 (KY550381). In terms of isolation source, S. haemolyticus MST1 was isolated from a traumatic wound, while P. aeruginosa MST2 and E. coli MST4 were procured from hernia surgical wounds, and K. pneumoniae MST3 and E. coli MST5 were obtained from diabetic foot ulcers. Antibiotic sensitivity tests exposed that K. pneumoniae MST3, E. coli MST4, and E. coli MST5 are extended-spectrum β-lactamases (ESBLs) bacteria. Moreover, S. haemolyticus MST1 belongs to the methicillin-resistant coagulase-negative staphylococcus (MRCoNS), whereas P. aeruginosa MST2 exhibited resistance to common empirical bactericidal antibiotics. Overall, the study provides new insights into the prevalent MDR bacteria in Egypt for further use as specific models in formulating antibacterial wound dressings.Entities:
Keywords: Extended-spectrum β-lactamases (ESBLs) bacteria; Klebsiella pneumoniae and Pseudomonas aeruginosa; Methicillin-resistant coagulase-negative staphylococcus haemolyticus (MRCoNS); Multidrug-resistant bacteria; Wound infections
Year: 2022 PMID: 35531185 PMCID: PMC9073052 DOI: 10.1016/j.sjbs.2022.01.015
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 2213-7106 Impact factor: 4.052
Fig. 1Schematic diagram exhibits the collection and isolation of MDR bacteria from different types of wounds and the procedures used to identify and characterize the most virulent bacteria.
Fig. 2(A) Bacterial isolates from different types of wounded skin, showing the incidence of Gram-negative and Gram-positive bacteria isolated from each type of wound. (B) Bacterial populations reveal the dominance of mono-bacterial infection throughout the collected samples. (C) Percentage of Gram-negative and Gram-positive bacteria obtained from the entire specimens, exhibiting the preponderance of Gram-negative bacteria. (D) Antibiotic susceptibility patterns of the MDR bacteria isolated from the infected wounds using the agar-disc diffusion method in relation to nine antibiotics, which belong to five classes of antibiotics with different mechanisms against pathogenic bacteria.
Antibiotic susceptibility patterns of MDR bacteria isolated from different types of wounds infected with pathogenic bacteria.
| 1 | (1) Hernia surgical wound | G-ve | Ak. | Am. /CL., Cef., Lev., Norf., Ofl., Peni.,Strept., Amp. |
| 2 | (1) Hernia surgical wound | G-ve | Am./Cl., Cef., Lev., Norf., Ofl., Peni., Strept., Amp., Ak. | |
| 3 | (2) Traumatic wound | G+ve | Am./Cl., Norf., Peni., Amp., Ak. | Cef., Lev., Ofl., Strept. |
| 4 | (3) Burn wound | G-ve | Lev., Ofl., Strept., Amp., Ak. | Am./Cl.,Cef., Norf., Peni. |
| 5 | (4) Traumatic wound | G-ve | Am./Cl., Cef., Lev., Norf., Ofl., Amp. | Peni., Strept. Ak. |
| 6 | (5) Caesarean section wound | G-ve | Lev., Ofl., Peni., Strept., Amp.,Ak. | Am./Cl., Cef., Norf. |
| 7 | (6) Surgical wound | G-ve | Cef., Lev., Norf., Ofl., Peni., Amp., Ak. | Am./Cl.,Strept. |
| 8 | (7) Surgical wound | G+ve | Cef., Lev., Norf., Amp., Ak. | Am./Cl., Ofl., Peni., Strept. |
| 9 | (8) Diabetic foot ulcer | G-ve | Ak. | Am./Cl., Cef., Lev., Norf., Ofl., Peni., Strept., Amp. |
| 10 | (9) Diabetic foot ulcer | G-ve | Lev., Norf. | Am./Cl., Cef., Ofl., Peni., Strept., Amp., Ak. |
| 11 | (9) Diabetic foot ulcer | G+ve | Am./Cl., Cef., Lev., Ofl., Strept., Amp., Ak. | Norf., Peni. |
| 12 | (10) Surgical wound | G-ve | Lev., Norf., Peni., Ak. | Am./Cl., Cef., Ofl., Strept., Amp. |
| 13 | (11) Traumatic wound | G+ve | Norf. | Am./Cl., Cef., Lev., Ofl., Peni., Strept., Amp., Ak. |
| 14 | (11) Traumatic wound | G-ve | Cef., Lev., Norf., Peni., Strept. | Am./Cl., Ofl., Amp., Ak. |
| 15 | (12) Surgical wound | G-ve | Cef., Lev., Norf., Ofl. Peni., Strept.,Amp. | Am./Cl., Ak. |
| 16 | (12) Surgical wound | G+ve | Cef., Lev., Norf., Ofl., Peni., Amp. | Am./Cl., Strep., Ak. |
| 17 | (13) Diabetic foot ulcer | G-ve | Am./Cl., Cef., Lev., Norf., Strept., Ak. | Ofl., Peni., Amp. |
| 18 | (14) Burn wound | G+ve | Am./Cl., Cef., Lev., Norf., Peni., Strept., Ak. | Ofl., Amp. |
| 19 | (14) Burn wound | G-ve | Am./Cl., Lev., Peni., Strept., Ak. | Cef., Norf., Ofl., Amp. |
| 20 | (14) Burn wound | G+ve | Am./Cl., Norf., Ofl., Peni., Amp., Ak. | Cef., Lev., Strept. |
| 21 | (15) Diabetic foot ulcer | G-ve | Am./Cl., Cef., Lev., Ofl., Strept., Amp., Ak. | Norf., Peni. |
| 22 | (15) Diabetic foot ulcer | G+ve | Cef., Lev., Ofl., Peni., Strept., Ak. | Am./Cl., Norf., Amp. |
Am./Cl. (Amoxicillin/clavulanic acid) (30 µg), Cef. (Cefoperazone) (75 µg), Lev. (Levofloxacin) (5 µg), Norf. (Norfloxacin) (10 µg), Ofl. (Ofloxacin) (5 µg), Peni. (Penicillin) (10 µg), Strept. (Streptomycin) (10 µg), Amp. (Ampicillin) (10 µg), Ak. (Amikacin) (30 µg).
Fig. 3Amplified 16S rRNA genes with sizes of approximately 1500 bp from the genomic DNA of S. haemolyticus MST1, P. aeruginosa MST2, K. pneumoniae MST3, E. coli MST4, and E. coli MST5.
Fig. 4Phylogenetic trees of (A) S. haemolyticus MST1 (KY550377) and (B) P. aeruginosa MST2 (KY550378) reveal their evolutionary relationships with regards to the closest bacteria on the basis of 16S rRNA nucleotide sequences retrieved from the GenBank database, and accession numbers of the sequences are indicated in parentheses. The phylogenetic trees were constructed employing the Neighbor-Joining tree with bootstrap values of 500 replicates, and the bars denote Jukes-Cantor distances of 0.5 and 0.2 for S. haemolyticus MST1 and P. aeruginosa MST2, respectively.
Fig. 5A phylogenetic tree of K. pneumoniae MST3 (KY550379) reveals its evolutionary relationships to the closest bacteria based on 16S rRNA nucleotide sequences retrieved from the GenBank database, with accession numbers of the sequences indicated in parentheses. The Phylogenetic tree was constructed by employing the Neighbor-Joining tree with bootstrap values of 500 replicates, and a bar denotes the Jukes-Cantor distance of 0.5.
Fig. 6Phylogenetic trees of (A) E. coli MST4 (KY550380) and (B) E. coli MST5 (KY550381) reveal their evolutionary relationships with regards to the closest bacteria on the basis of 16S rRNA nucleotide sequences retrieved from the GenBank database, and accession numbers of the sequences are indicated in parentheses. The phylogenetic trees were constructed employing the Neighbor-Joining tree with bootstrap values of 500 replicates, and the bars denote Jukes-Cantor distances of 0.5 and 0.2 for E. coli MST4 and E. coli MST5, respectively.
Phenotypic properties of S. haemolyticus MST1, P. aeruginosa MST2, K. pneumoniae MST3, E. coli MST4, and E. coli MST5 using VITEK 2.
| Test | Test | ||||||
|---|---|---|---|---|---|---|---|
| 1 | Ala-phe-pro-arylamidase | – | Ala-phe-pro-arylamidase | – | – | – | – |
| 2 | Alpha-mannosidase | – | Adonitol | – | + | – | – |
| 3 | L-Pyrrolydonyl-arylamidase | + | L-Pyrrolydonyl-arylamidase | – | + | – | – |
| 4 | LeucineArylamidase | – | L-Arabitol | – | – | – | – |
| 5 | Beta-glucuronidase | – | D-Cellobiose‘ | – | + | – | – |
| 6 | Beta-galactosidase | – | Beta-galactosidase | – | + | + | + |
| 7 | D-Amygdalin | – | H2S production | – | – | – | – |
| 8 | Phosphatidylinositol Phospholipase C | – | Beta-n-acetyl glucosaminidase | – | – | – | – |
| 9 | D-Xylose | – | Glutamylarylamidasepna | – | – | – | – |
| 10 | Arginine Dihydrolase 1 | + | D-glucose | + | + | + | + |
| 11 | Cyclodextrin | – | Gamma-glutamyl-transferase | + | + | – | – |
| 12 | L-Aspartate Arylamidase | – | Fermentation/ glucose | – | + | + | + |
| 13 | Beta Galactopyranosidase | – | Beta-glucosidase | – | + | – | – |
| 14 | D-Maltose | + | D-Maltose | – | + | + | + |
| 15 | D-mannitol | + | D-mannitol | + | + | + | + |
| 16 | D-mannose | – | D-mannose | + | + | + | + |
| 17 | Methyl-B-D-Glucoyranosidase | – | Beta-xylosidase | – | – | – | – |
| 18 | Pullulan | – | Beta-alanine arylamidasepna | + | – | – | – |
| 19 | L-prolinearylamidase | – | L-proline arylamidase | + | + | – | – |
| 20 | Lactose | + | Lipase | – | – | – | – |
| 21 | N-acetyl-D-Glucosamine | + | Palatinose | – | + | – | – |
| 22 | Tyrosine arylamidase | – | Tyrosine arylamidase | + | + | + | – |
| 23 | Urease | – | Urease | – | + | – | – |
| 24 | D-sorbitol | – | D-sorbitol | – | + | + | + |
| 25 | Saccharose/Sucrose | + | Saccharose/sucrose | – | + | + | + |
| 26 | Salicin | – | D-tagatose | – | – | – | – |
| 27 | D-trehalose | + | D-trehalose | – | + | + | + |
| 28 | Bacitracin Resistance | + | Citrate (sodium) | + | + | – | – |
| 29 | Novobiocin | – | Malonate | + | + | – | – |
| 30 | Growth In 6.5% NaCl | + | 5-Keto-d-gluconate | – | – | – | – |
| 31 | L-lactate alkalinisation | + | L-lactate alkalinisation | + | + | + | – |
| 32 | Alpha-glucosidase | + | Alpha-glucosidase | – | – | – | – |
| 33 | Arginine Dihydrolase 2 | – | Succinate alkalinisation | + | + | + | – |
| 34 | Optochin Resistance | + | Beta-n-acetyl-galactosaminidase | – | – | – | – |
| 35 | Alpha-galactosidase | – | Alpha-galactosidase | – | + | + | – |
| 36 | Phosphatase | – | Phosphatase | – | + | – | – |
| 37 | Polymixin B Resistance | – | Glycine arylamidase | – | + | – | – |
| 38 | D-Galactose | + | Ornithine decarboxylase | – | – | – | + |
| 39 | D-Ribose | + | Lysine decarboxylase | – | + | + | + |
| 40 | Alanine Arylamidase | – | L-histidine assimilation | + | – | – | – |
| 41 | D-Raffinose | – | Coumarate | + | – | + | + |
| 42 | Beta-glucoronidase | – | Beta-glucoronidase | – | – | + | + |
| 43 | O/1 29 resistance (comp.vibrio.) | + | O/1 29 resistance (comp.vibrio.) | + | + | + | + |
Antibiotic susceptibility patterns of S. haemolyticus MST1, P. aeruginosa MST2, K. pneumoniae MST3, E. coli MST4, and E. coli MST5 using VITEK 2.
| Antibiotic | |||||
|---|---|---|---|---|---|
| Cefoxitin screen | +ve | – | – | – | – |
| Benzylpenicillin | R | – | – | – | – |
| Oxacillin | R | – | – | – | – |
| Imipenem | R | *I | R | S | S |
| Gentamicin | R | – | – | – | – |
| Ciprofloxacin | R | – | – | – | – |
| Moxifloxacin | I | – | – | – | – |
| Inducible Clindamycin Resistance | -ve | – | – | – | – |
| Erythromycin | R | – | – | – | – |
| Clindamycin | S | – | – | – | – |
| Linezolid | S | – | – | – | – |
| Teicoplanin | S | – | – | – | – |
| Vancomycin | S | – | – | – | – |
| Tetracycline | S | – | – | – | – |
| Tigecycline | S | – | – | – | – |
| Fosfomycin | R | – | – | – | – |
| Fusidic Acid | R | – | – | – | – |
| Rifampicin | S | – | – | – | – |
| Trimethoprim/Sulfamethoxazole | R | R | R | R | R |
| Ticarcillin | – | R | – | – | – |
| Ticarcillin/Clavulanic Acid | – | R | – | – | – |
| Piperacillin | – | R | – | – | – |
| Ceftazidime | – | I | – | – | – |
| Pefloxacin | – | R | – | – | – |
| Minocycline | – | R | – | – | – |
| Colistin | – | S | – | – | – |
| Meropenem | – | I | S | S | S |
| Amikacin | – | R | S | S | S |
| Gentamicin | – | R | R | R | S |
| Tobramycin | – | S | R | R | S |
| Ciprofloxacin | – | R | I | R | S |
| Cefepime | – | S | *R | *R | *R |
| ESBL | – | – | +ve | +ve | +ve |
| Ampicillin | – | – | R | R | R |
| Ampicillin / Sulbactam | – | – | R | R | S |
| + Cefotaxime | – | – | R | R | R |
| Ceftriaxone | – | – | R | R | R |
| Cefazolin | – | – | R | R | R |
| Aztreonam | – | – | R | *R | R |
| Moxifloxacin | – | – | S | R | S |
| Ertapenem | – | – | R | S | S |
| Nitrofurantoin | – | – | S | I | S |
| Tigecycline | – | – | R | S | S |
+ve = Deduced drug; * =AES modified; R = Resistant; S = Sensitive; I = Intermediate; - = not applicable.